

CELL SURFACE ANTIGENS OF CHEMICALLY INDUCED SARCOMAS OF THE MOUSE

I. Murine Leukemia Virus-Related Antigens and Alloantigens on Cultured Fibroblasts and Sarcoma Cells: Description of a Unique Antigen on BALB/c Meth A Sarcoma*

By ALBERT B. DeLEO,† HIROSHI SHIKU, TOSHITADA TAKAHASHI, MARY JOHN, AND
LLOYD J. OLD

(From the Memorial Sloan-Kettering Cancer Center, New York, New York 10021)

The first evidence for tumor-specific antigens came from transplantation studies of sarcomas induced by methylcholanthrene in inbred mice (1-5). Growth of a sarcoma transplant in syngeneic recipients, followed by its removal, increased resistance to subsequent challenge with the same sarcoma. The surprising feature that emerged from the study of these transplantation antigens is that they are distinct for each tumor, no two tumors having been convincingly shown to share the same antigen. Although repeated immunization with tumor cells can lead to substantial resistance to tumor challenge, antibody to the unique antigens of chemically induced sarcomas has been difficult to demonstrate in mice and, where positive results have been obtained, the analysis was not sufficiently detailed to indicate the class of surface antigen being detected. The fact that murine leukemia virus (MuLV)¹ and its antigens are often found in chemically induced sarcomas (6-8) and that normal mouse serum frequently contains naturally occurring antibody to MuLV antigens (9-11) adds a serious complication to the serological study of these tumors and makes it virtually impossible to interpret past studies where this was not taken into consideration. Apparently, MuLV-related antigens on chemically induced tumors are not effective in eliciting transplantation resistance or cross reactions between different sarcomas would have been a far more common finding.

To initiate a serological analysis of the unique surface antigens of chemically induced sarcomas, we have established a number of fibroblast and sarcoma cell lines in tissue culture and have defined the surface phenotype of these cells with regard to known MuLV and alloantigenic markers. With this background, it has been possible to characterize a unique cell surface antigen on Meth A, the widely studied BALB/c methylcholanthrene-induced sarcoma.

Materials and Methods

Animals. Female mice, 2-5 mo old, were obtained from the following sources: A/Thy-1.1 and 129 strain mice were from our breeding colony, BALB/c, C57BL/6, and other inbred strains from

* Supported in part by grants CA-08748 and CA-17404 from the National Cancer Institute.

† Recipient of a fellowship from the Cancer Research Institute, Inc.

¹ *Abbreviations used in this paper:* FBS, fetal bovine serum; GSCA, Gross cell surface antigen; MS, methylcholanthrene sarcoma; MuLV, murine leukemia virus; RDDP, RNA-dependent DNA polymerase; TNF, tumor necrosis factor.

The Jackson Laboratory, Bar Harbor, Maine, and random bred Swiss ICR from Camm Research Institute, Inc., Wayne, N. J.

Tumors. Sarcomas were induced in 2-mo-old female mice by a single subcutaneous injection of 0.1 mg 3-methylcholanthrene (Eastman Kodak Co., Rochester, N. Y.) dissolved in 0.1 ml sesame oil. They were maintained by serial transplantation in the strain of origin or stored in liquid nitrogen. With the exception of the Meth A and Meth 4 sarcomas, the newly derived sarcomas are distinguished by an initial letter or letters indicating their strain of origin (C = BALB/c, B6 = C57BL/6, CB6 = [BALB/c × C57BL/6]F₁) and by the abbreviation MS (methylcholanthrene sarcoma).

Meth A was induced in a BALB/c female mouse in 1960 (5). An ascites variant of the solid tumor was obtained in 1961 and has been in continuous *in vivo* transplantation since that time. The original solid Meth A sarcoma has been stored at intervals in liquid nitrogen and was used in the present studies during *in vivo* passages 110-140.

Meth 4 was induced in a C57BL/6 female mouse in 1972 (12), and studied during *in vivo* passages 1-10. CMS1,3,4,5,7,14, and 21 were induced in BALB/c mice in 1975, and studied during *in vivo* passages 1-20. B6MS1,2,4, and 5 were induced in C57BL/6 mice in 1975, and studied during *in vivo* passages 1-10. CB6MS1 and 2 were induced in (BALB/c × C57BL/6)F₁ mice in 1975, and studied during *in vivo* passage 1.

The F9 and PYS culture lines were derived from a teratocarcinoma of 129/Sv origin and were provided by Dr. K. Artzt. The other tumor lines used in this study were serially passaged in mice and have been described in previous publications (13-15).

Culture Medium. Eagle's complete minimum essential medium was supplemented with 2 mM L-glutamine, 1% nonessential amino acids, 100 U penicillin/ml, 100 µg streptomycin/ml, and 10% fetal bovine serum (FBS).

Cell Cultures. Cell cultures were derived from whole fetuses (14 days), lung fibroblasts of 12- to 16-wk-old mice or transplanted sarcomas as described by Shiku et al. (12). Meth A(a) and Meth A(s) refer to culture lines established from Meth A ascites and Meth A solid sarcoma.

The surface phenotype of the cultured cells was determined after the cells achieved a stable growth pattern *in vitro* and most tests were conducted on lines between the 10th and 30th passage generation.

Antisera to MuLV-Related Antigens and Known Alloantigens. Details of the serological typing systems used for determining the cell surface antigens of fibroblast and sarcoma cells are given in Table I. The following antisera were used in microcytotoxicity tests: goat anti-MuLV (Rauscher) p30, goat anti-MuLV (Rauscher) gp70, and (W/Fu × BN)F₁ anti-W/Fu leukemia (C58NT)D = anti-NTD. (The goat antisera were obtained from Dr. R. Wilsnack, Huntington Research Laboratories, Brookville, Md.) The specificity of these MuLV antisera has been verified by extensive studies in our laboratory.

Antisera to Meth A Antigen. Two methods of antiserum production resulted in antibody to the unique antigen of Meth A sarcoma. The first method involved intraperitoneal injections of 5×10^6 irradiated Meth A ascites cells once weekly for 5 wk in BALB/c or (BALB/c × C57BL/6)F₁ recipients followed by five weekly intradermal challenges of increasing numbers of nonirradiated Meth A ascites cells (2×10^5 - 1×10^6 cells). The second method took advantage of the sensitivity of Meth A sarcoma to the tumor necrosis factor (TNF) present in the serum of *Bacillus Calmette-Guérin*-infected mice injected with endotoxin (for details of TNF production see reference 25). (BALB/c × C57BL/6)F₁ mice received 3×10^5 Meth A ascites cells injected intradermally. When tumors reached approximately 7-8 mm in average diameter, the mice received 0.5 ml TNF⁺ serum injected *i.v.* Approximately 25% of TNF-treated mice showed complete regression of their tumors and these animals were subsequently injected intraperitoneally at 2-wk intervals with viable Meth A ascites cells starting with 5×10^5 and increasing to 5 - 10×10^6 . Mice that remained tumor-free through the immunization period were bled individually and their serum titered on Meth A ascites cells and Meth A(a) cultured cells.

Cytotoxic Tests. (a) For cells in suspension, the conventional cytotoxic test was used (13, 17, 26). (b) For monolayer cultured cells, a modification of the microcytotoxicity test described by Bloom was used (27). Monolayer cells were detached with 0.05% Tryptar (Armour Pharmaceutical Co., Chicago, Ill.) in Puck's saline A solution, washed in culture medium, and the concentration of viable cells adjusted to 2×10^4 cells/ml in culture medium. A 10-µl cell suspension containing 200 target cells was distributed with either a microliter syringe and dispenser (Hamilton Company

TABLE I
Description of Serological Typing Systems for Detecting Cell Surface Antigens of Fibroblast and Sarcoma Cell Lines by Absorption Tests

| Antigenic system | Antiserum (dilution)* | Standard test cell | Complement source (serum dilution) | Reference |
|------------------------------|--|----------------------------------|------------------------------------|-----------|
| MuLV-Related antigens | | | | |
| G _{IX} | Rat (W/Fu × BN) _F ₁ anti-W/Fu leukemia (C58NTD) (anti-NTD) (1:150) | 129 thymocytes | Rabbit (1:12) | 16, 17 |
| GCSA | C57BL/6 anti-transplanted spontaneous AKR leukemia K36 (1:10) | E _δ G2 leukemia cells | Guinea pig (1:2) | 13 |
| Alloantigens | | | | |
| H-2.2 (H-2D ^b) | (BALB/c × HTD) _F ₁ anti-EL4 (1:10)‡ | C57BL/6 lymph node cells | Guinea pig (1:4) | 18 |
| H-2.33 (H-2K ^b) | (B10.A × HTG) _F ₁ anti-EL4 (1:60)‡ | C57BL/6 lymph node cells | Guinea pig (1:4) | 18 |
| H-2.4 (H-2D ^d) | BALB.G anti-BALB/c (1:10)‡ | BALB/c lymph node cells | Guinea pig (1:4) | 18 |
| H-2.31 (H-2K ^d) | (A × BALB.B) _F ₁ anti-BALB/c (1:20)‡ | BALB/c lymph node cells | Guinea pig (1:4) | 18 |
| Ia.7 | A.TH anti-A.TL (1:20)§ | BALB/c lymph node cells | Guinea pig (1:4) | 19, 20 |
| Lyt-1.2 | C3H anti-CE thymocytes (1:50) | C57BL/6 thymocytes | Rabbit (1:15) | 21, 22 |
| Lyt-2.2 | (C3H × B6-Ly-2.1) _F ₁ anti-ERLD (1:100) | C57BL/6 thymocytes | Rabbit (1:15) | 21, 22 |
| PC.1 | (DBA/2 × C57BL/6) _F ₁ anti-MOPC-70A (1:8) | MOPC-70A | Guinea pig (1:2.5) | 15 |
| Thy-1.2 | (A-Thy-1.1 × AKR-H-2 ^b) _F ₁ anti-ASL1 (1:160) | A thymocytes | Rabbit (1:15) | 22, 23 |
| TL.2 | (A-TL ⁻ × C57BL/6) _F ₁ anti-ASL1 (1:400) | BALB/c thymocytes | Rabbit (1:15) | 24 |

* Dilution used for absorption tests.

‡ Obtained from Dr. F. Lilly, Albert Einstein College of Medicine, New York.

§ Obtained from Dr. D. C. Schreffler, Washington University Medical School, St. Louis, Mo.

Inc., Whittier, Calif.) or a 1-ml disposable glass syringe (no. 704S, Beckton-Dickinson & Co., Rutherford, N. J.) into the wells of Falcon Microtest Plates (no. 3034, Falcon Plastics Division of BioQuest, Oxnard, Calif.). The plates were then incubated at 37°C in 5% CO₂ in humidified air for 18 h. Medium was removed by blotting with a gauze sponge, and 10 μl of the appropriate dilution of antiserum and 10 μl selected rabbit serum (1/20–1/30) as complement source (each diluted in cultured medium with 10% heat inactivated FBS) were added. After further incubation for 18 h, the plates were again blotted with gauze sponge, fixed with absolute methanol, and stained with 2% Giemsa stain (Fisher Scientific Co., Pittsburgh, Pa.) in 0.08 M sodium phosphate buffer (pH 7.2).

For analysis of the Meth A antigen, sensitization with antiserum before addition of complement augmented cytotoxicity and resulted in higher antiserum titers. Thus in all tests recorded here, cultured Meth A(a) cells were presensitized with antiserum for 30 min at 37°C in 5% CO₂ in humidified air. Antiserum was then removed with a gauze sponge and complement was added followed by an 18-h incubation period, as above.




FIG. 1. Microcytotoxicity tests for MuLV-related antigens on fibroblast and sarcoma cell lines of BALB/c and C57BL/6 (B6) origin.

Tests were performed in duplicate along with appropriate media, antiserum, and complement controls. Plates were analyzed microscopically and the percentage cytotoxicity of a given antiserum dilution was calculated as follows:

$$\text{Percent cytotoxicity} = \left[1 - \frac{\text{number of cells in well treated with antiserum and complement}}{\text{number of cells in well treated with culture medium alone}} \right] \times 100.$$

Antisera controls showed $\leq 5\%$ cytotoxicity and complement controls were in the range of 5–15% cytotoxicity.

Absorption Tests. These were performed according to methods developed in our laboratory (13, 17, 26). The dilution of antiserum chosen for absorption tests was generally two doubling dilutions below its end point (50% cytotoxicity), as determined in preliminary tests. Equal volumes of diluted antiserum and packed washed cells were incubated together, with frequent shaking, for 30 min at 4°C. After removal of the absorbing cells by centrifugation, the residual cytotoxic activity of the serum was tested. Monolayer cells were harvested for absorption tests by treating cultures with 0.05% EDTA.

XC Plaque Assay for Ecotropic MuLV. Culture fluids were tested by the method of Rowe et al. (28).

RNA-Dependent DNA Polymerase (RDDP) Assay. Culture fluids were tested by the method of Stephenson et al. (29).

Results

MuLV Expression by Cultured Fibroblasts and Sarcomas. The cultured cell lines were assayed for MuLV expression by (a) microcytotoxic tests with polyvalent anti-MuLV serum (anti-NTD) and with antiserum to MuLV structural components gp70 and p30 (Fig. 1), (b) absorption tests for two type-specific cell surface antigens specified by MuLV, G_{IX} , and Gross cell surface antigen (GCSA) (Fig. 2). (c) XC assays for infectious MuLV ecotropic virus and (d) assays for




FIG. 2. Typing of BALB/c fibroblast and sarcoma cell lines for GCSA and G_{IX} cell surface antigens by absorption tests. E δ G2, a GCSA⁺ MuLV (Gross)-induced leukemia of C57BL/6 origin, and AKR thymocytes, a G_{IX} ⁺ cell population, were included as positive control cells.

RDDP. Table II summarizes the results of these tests for MuLV and MuLV-related antigens.

Cell lines of BALB/c origin could be classified MuLV⁻ or MuLV⁺ on the basis of these several assays, and the expression of MuLV antigens invariably correlated with the presence of infectious MuLV and RDDP activity. In contrast, cell lines of C57BL/6, A and (BALB/c \times C57BL/6) F_1 origin reacted with anti-gp70 even though they showed no other evidence of MuLV infection. Mice of these strains are known to express a gp70 molecule on the surface of their cells that is not dependent on productive MuLV infection (30). This selective expression of a portion of the viral genome is not seen with BALB/c cells, where either the full range of MuLV gene products were present or no viral markers could be detected.

In this study, 6 of the 11 lines of sarcoma cells typed MuLV⁺ by all assays. This does not appear to relate to length of time these tumors were passaged in vivo before tissue culture. For example, the line derived from the long-transplanted Meth A ascites (Meth A(a)) was MuLV⁻, whereas CMS1 and CMS3 of more recent derivation were MuLV⁺. No discernible difference in the growth or morphology of MuLV⁺ or MuLV⁻ sarcoma cells was evident.

With regard to the stability of the MuLV phenotype of culture lines, 11 sarcoma cell lines were repeatedly tested over a 10-mo period with consistent

TABLE II
*Expression of MuLV and MuLV-Related Antigens by Fibroblast and Sarcoma Cell Lines:
 Summary of Results*

| Strain | Cell line | Direct microcyto- toxicity tests | | | Absorption tests | | XC Assay for ecotropic MuLV | RDDP Assay |
|-------------------------------------|----------------------------------|-------------------------------------|--------------|---------------|---------------------|------|-----------------------------------|---------------|
| | | Anti- NTD | Anti- p30 | Anti- gp70 | G _{TX} | GCSA | | |
| BALB/c | Fetal fibroblasts | - | - | - | - | - | - | - |
| | Adult lung fibro- blasts (I) | - | - | - | - | - | - | - |
| | Adult lung fibro- blasts (II) | + | + | + | + | + | + | + |
| | CMS1 sarcoma | + | + | + | + | + | + | + |
| | CMS3 sarcoma | + | + | + | + | + | + | + |
| | CMS4 sarcoma | - | - | - | - | - | - | - |
| | CMS5 sarcoma | - | - | - | - | - | - | - |
| | Meth A(a) sar- coma | - | - | - | - | - | - | - |
| | Meth A(s) sar- coma | + | + | + | + | + | + | + |
| C57BL/6 | Fetal fibroblasts | - | - | + | - | - | - | - |
| | Adult lung fibro- blasts | - | - | + | - | - | - | - |
| | Meth 4 | + | + | + | + | + | + | + |
| | B6MS2 sarcoma | + | + | + | + | + | + | + |
| | B6MS5 sarcoma | - | - | + | - | - | - | - |
| (BALB/c × C57BL/6)F ₁ | CB6MS1 sarcoma | - | - | + | - | - | - | - |
| | CB6MS2 sarcoma | + | + | + | + | + | + | + |
| A | Adult lung fibro- blasts | - | - | + | - | - | - | - |

results. One BALB/c fibroblast line, however, showed a spontaneous MuLV⁻ to MuLV⁺ conversion after 6 mo in tissue culture. This was accompanied by changes associated with transformation (i.e., more rapid growth rate and greater saturation density of the cultured cells).

Cell Surface Alloantigens of Cultured Fibroblasts and Sarcomas. The fibroblast and sarcoma cell lines were typed for known cell surface alloantigens by absorption tests. Table III summarizes these results. (Because the typing antisera contain antibody to MuLV-related antigens, MuLV⁺ cell lines cannot be typed in direct cytotoxic tests. This does not interfere, however, with typing by absorption.)

H-2D AND H-2K ALLOANTIGENS. All cell lines expressed the appropriate H-2D and H-2K private specificity.

Thy 1.2. Fig. 3 illustrates absorption tests for Thy-1.2. AKR thymocytes (phenotype Thy-1.1) and B6 thymocytes (phenotype Thy-1.2) were included as negative and positive control cells. On the basis of these tests, fibroblasts and sarcoma cells can be clearly typed Thy-1.2⁻ or Thy-1.2⁺.

TABLE III
Cell Surface Alloantigens of Cultured Fibroblast and Sarcoma Cell Lines as Determined by Absorption Analysis: Summary of Results

| Strain | Cell line | H-2.4 (H-2D ^d) | H-2.31 (H-2K ^d) | H-2.2 (H-2D ^b) | H-2.33 (H-2K ^b) | Thy-1.2 | PC.1 | Lyt-1.2 | Lyt-2.2 | Ia.7 | TL.2 |
|---------|-----------------------------|-------------------------------|--------------------------------|-------------------------------|--------------------------------|---------|------|---------|---------|------|------|
| BALB/c | Adult lung fibroblasts (I) | + | + | - | - | + | + | - | - | - | - |
| | Adult lung fibroblasts (II) | + | + | - | - | + | + | - | - | - | - |
| | CMS1 sarcoma | + | + | - | - | - | - | - | - | - | - |
| | CMS3 sarcoma | + | + | - | - | + | - | - | - | - | - |
| | CMS4 sarcoma | + | + | - | - | + | - | - | - | - | - |
| | CMS5 sarcoma | + | + | - | - | + | - | - | - | - | - |
| | Meth A(a) | + | + | - | - | - | - | - | - | - | - |
| | Meth A(s) | + | + | - | - | - | + | - | - | - | - |
| C57BL/6 | Adult lung fibroblasts | - | - | + | + | + | - | - | - | - | - |
| | B6MS2 | - | - | + | + | - | - | - | - | - | - |
| | Meth 4 | - | - | + | + | - | - | - | - | - | - |




FIG. 3. Typing of BALB/c fibroblast and sarcoma cell lines for Thy-1.2 and PC.1 alloantigens by absorption tests. C57BL/6 (B6) thymocytes (Thy-1.2⁺) and AKR thymocytes (Thy-1.2⁻) were included as control cells for Thy-1.2 tests. BALB/c liver (PC.1⁺) and B6 liver (PC.1⁻) were included as control cells for PC.1 tests.

PC.1. Fig. 3 illustrates absorption tests for PC.1. B6 liver (PC.1⁻) and BALB/c liver (PC.1⁺) were included as negative and positive absorbing tissues. Two BALB/c lung fibroblast lines and Meth A(s), the cell line derived from the solid Meth A sarcoma, typed PC.1⁺. In contrast, Meth A(a), the line derived from the Meth A ascites tumor, was PC.1⁻.




FIG. 4. Microcytotoxicity tests of (BALB/c \times C57BL/6) anti-Meth A serum on MuLV⁻ fibroblast and sarcoma cell lines of BALB/c origin.

TL.2, LYT-1, LYT-2, Ia-7. These alloantigens were not demonstrable on any fibroblast or sarcoma cell line.

The Meth A Antigenic System. A number of syngeneic antisera have been prepared against individual BALB/c or C57BL/6 sarcomas. Regardless of the MuLV phenotype of the immunizing sarcoma, the resulting antisera invariably contained cytotoxic antibody to MuLV-related antigens and were reactive with MuLV⁺ fibroblast or sarcoma cell lines. Because of this, our search for sarcoma-specific antigens focuses on MuLV⁻ sarcoma lines of BALB/c origin so that reactions due to MuLV antibody will not confound the serological analysis. The first antigen to be defined in this way is the unique antigen of Meth A sarcoma.

DIRECT CYTOTOXIC TESTS WITH METH A ANTISERA. Antisera prepared in BALB/c or (BALB/c \times C57BL/6)_F₁ mice by repeated inoculations of Meth A ascites cells were cytotoxic for Meth A ascites cells as well as for the MuLV⁻ tissue culture line derived from Meth A ascites sarcoma. The antisera had little or no cytotoxic activity for other MuLV⁻ cultured cells of BALB/c origin (Fig. 4).

ABSORPTION ANALYSIS OF METH A ANTISERA. Fig. 5 illustrates absorption tests with Meth A antisera and Table IV summarizes the results of the extensive absorption analysis that defines the Meth A system. The Meth A antigen is restricted to the ascites and solid forms of Meth A sarcoma and the culture lines derived from them. It has not been found on any other normal or neoplastic cell type.

TESTS FOR METH A ANTIGEN ON NORMAL LYMPHOID CELLS. It has recently been suggested that the transplantation antigens of chemically induced tumors represent derepressed or altered products of the *H-2* complex (31-33). The absorption tests summarized in Table IV give no support to the idea that the Meth A antigen is related to histocompatibility antigens normally expressed by other mouse strains, since the spleen cells of 14 different inbred strains lacked Meth A antigen. These strains represent six independent *H-2* haplotypes and the majority of known private and public specificities defined by the *H-2* complex. To




FIG. 5. Absorption analysis of (BALB/c \times C57BL/6)F₁ anti-Meth A serum. (a) tests with BALB/c sarcomas passaged in vivo, (b) tests with syngeneic and allogeneic leukemia and myeloma cells and (c) tests with syngeneic and allogeneic normal spleen cells. Absorbed antisera assayed for residual cytotoxicity on Meth A(a) cultured cells.

exclude the possibility that the Meth A absorption system detects more than one determinant and that normal cells express only one of them and therefore fail to absorb Meth A reactivity, the Meth A antiserum was tested for direct cytotoxicity on normal lymphoid cells from spleen and thymus. No cytotoxic reactions were observed with cells from the following strains of mice: A, BALB/c, B10.A, C3H/An, C57BL/6, RF, PL, SJL, Swiss, SWR, and 129.

Discussion

In contrast to the detailed knowledge we have of the surface antigens of normal and neoplastic lymphoid cells of the mouse (34), far less is known about the antigens that characterize the surface of fibroblast and sarcoma cells. The greater sensitivity of lymphoid cells to cytotoxic antibody and the ease of working with cells that remain in free suspension (rather than with cells like fibroblasts that adhere to glass) clearly account for the past emphasis on lymphoid populations. Serological analysis of lymphocytes, particularly those of thymic derivation, has uncovered a series of surface antigens that are restricted to cells that have undergone this pathway of differentiation (hence the designation differentiation antigens to distinguish antigens that characterize different cell populations). Alloantigens belonging to the Lyt family, of which four separate systems have now been defined and several others identified but not as yet analyzed, are prime examples of differentiation antigens on T lymphocytes (35). The presumption is that these surface molecules play a critical role in the interactions involved in differentiated cellular function and that all specialized cell types will be marked by a uniquely characteristic display of surface anti-

TABLE IV
Absorption Analysis of (BALB/c × C57BL/6)F₁ Anti-Meth A Serum: Summary of Results*

| Positive absorptions | Negative absorptions | | | |
|------------------------------------|---|--|---|---|
| | Source of cells | | Source of cells | |
| Source of cells | In vivo | | In vitro | |
| | Normal | Tumor | Normal | Tumor |
| In vivo Meth A (ascites) | Spleen A AKR BALB/c (BALB/c × C57BL/6)F ₁ C57BL/6 C3H/He DBA/2 LP | Spontaneous leukemias ASL1 K36 SL-2 Radiation-induced leukemias RADA1 RL ³ 1 ERLD EARAD1 | Chemically-in- duced sarcomas CMS1 CMS3 CMS4 CMS5 CMS6 CMS7 CMS14 CMS21 | Chemically-induced sarcomas CMS1 CMS3 CMS4 CMS5 B6MS2 Meth 4 Teratocarcinoma F9 PYS |
| In vitro Meth A(a) Meth A(s) | Thymus AKR BALB/c Fetus Swiss (11 day) BALB/c (15 day) Xenogenic Sheep erythrocytes Human erythrocytes (types AB, O) Human fetal brain Guinea pig kidney | Chemically-induced leukemia EL4 C57BL MuLV (Gross)-Induced leukemia E ₅ 62 C57BL/6 Spontaneous mammary tumor SMT-2 DBA/2 Myeloma MOPC-70 BALB/c | Adult lung fibroblasts A AKR BALB/c(LI) (BALB/c × C57BL/6)F ₁ C57BL/6 C3H/He MA/My PL Fetal fibroblasts BALB/c | Chemically-induced sarcomas CMS1 CMS3 CMS4 CMS5 B6MS2 Meth 4 Teratocarcinoma F9 PYS |

* Absorbed antisera assayed for residual cytotoxicity on Meth A(s) cultured cells.

† Strain of origin.

gens. Whether this conclusion can be extended to other cell populations is now the subject of considerable interest. Because the fibroblast establishes itself in vitro with relative ease and can be derived from different organs and from mice of different ages, it is a particularly attractive model for such studies. In addition, as much of our current thinking about malignant transformation has come from in vitro studies with fibroblasts, the development of a comprehensive serology for the cell surface antigens of fibroblasts would provide valuable immunogenetic probes with possibly greater resolving power than lectins to analyze the surface modifications that accompany the malignant change.

With the widespread occurrence of MuLV in the mouse, the possible contribution of MuLV antigens must always be considered in interpreting results of immunological analysis of mouse cells, whether normal or malignant, and this is true whether one is working with serological techniques or those measuring cell-mediated immunity. Although it has been known for some time that sarcomas induced by chemical carcinogens may express cell surface antigens related to MuLV, this has not been the subject of any detailed study. Before attempting to define new surface alloantigens or tumor-specific antigens on sarcoma cells, it is essential to characterize the MuLV phenotype of the target cell. All mouse serum, whether from immunized donors or not, must be suspected of having antibodies to surface MuLV antigens, and we have not as yet found any reliable or routine method to eliminate them. Cells expressing MuLV are, therefore, generally unsuitable as target cells for detecting non-MuLV antigens in direct cytotoxic tests; positive reactions with mouse sera may be due to the presence of MuLV antibody and appropriate absorption tests are necessary to resolve the issue of specificity. For this reason, the availability of MuLV⁻ fibroblast and MuLV⁻ sarcoma lines greatly facilitates search for surface antigens unrelated to MuLV.

What significance can be attributed to the appearance of MuLV in sarcomas arising in strains (such as BALB/c) that normally do not express these endogenous viral genes? Does it reflect the general tendency of malignant cells to show instability in genetic control of the differentiated state, resulting in the activation of ordinarily silent genes, or is it of etiological significance, with MuLV playing a critical role in chemical carcinogenesis, a suggestion that continues to attract attention? The fact that some sarcomas express MuLV and others do not, even though they all presumably carry MuLV genes, indicates that MuLV activation is not an invariable consequence of malignant transformation. Nor is MuLV activation restricted to sarcomas, since some morphologically normal fibroblast lines become MuLV⁺ during passage in tissue culture. In BALB/c mice, full expression of the viral genes and the antigens they determine appears to be the case under conditions of MuLV activation. Thus, the surface phenotype of MuLV⁺ sarcoma or fibroblast lines is G_{IX}⁺ GCSA⁺ gp70⁺ p30⁺. We did not find any instance of partial expression of MuLV (e.g., G_{IX}⁺ GCSA⁻) as if only part of the viral genome was activated. In contrast, C57BL/6 fibroblasts and sarcomas carry a gp70-like molecule on their surface, whether they express other MuLV traits or not. This gp70 of C57BL/6 cells is most likely related to the 0-gp70 molecule that has been detected on normal C57BL/6 lymphoid and leukemia cells (30) and appears to be the product of a separate MuLV locus in this strain. With the recognition that there is far more MuLV polymorphism than was

originally suspected, it will be important to characterize the MuLV from fibroblast and sarcoma cultures to determine whether they can be distinguished from MuLV derived from normal or leukemic lymphoid tissues.

Of the differentiation alloantigens studied, Thy-1 and PC.1 have been detected on some fibroblast and sarcoma cell lines. These antigens may not be stable markers for cultured fibroblasts since we have observed the loss of Thy-1 and PC.1 from fibroblast cultures that in earlier passages typed Thy-1⁺ and PC.1⁺ by absorption. Another explanation for this finding could be that fibroblasts are dimorphic for these alloantigens and that the emergence of Thy-1⁻ or PC.1⁻ cultures represents the outgrowth of one cell type from an originally mixed population. Either explanation (instability and loss of antigen expression in vitro or dimorphic populations of normal fibroblasts) could account for the finding of Thy-1⁺ or ⁻ and PC.1⁺ or ⁻ sarcoma lines. As expected, alloantigens belonging to the TL and Lyt systems that characterize cells of thymic origin were not detected on fibroblast or sarcoma cells. Given this information on known alloantigens, it should be possible to develop a series of planned immunizations in mice of various genotypes to uncover new surface alloantigens of fibroblasts and sarcoma cells.

A remarkable and baffling feature of chemically induced sarcomas is the extensive range of antigens that have been detected by transplantation immunity in syngeneic mice. Since the discovery of this class of tumor antigens, sarcomas induced by a variety of chemical carcinogens have been the object of intense scrutiny by tumor immunologists and yet not a single instance of a bona fide sharing of antigen by two tumors, even when induced in the same mouse (36), has been established. There has been much discussion concerning the basis of this extensive antigenic diversity. Whether these unique surface antigens have their origin in carcinogen- or malignancy-induced changes in structural or regulatory genes, or arise from epigenetic errors in membrane synthesis is not known. Clearly, their analysis would be greatly facilitated if serological methods for detecting them were devised. The present study of BALB/c Meth A sarcoma represents an attempt to define serologically the strong transplantation antigen carried by this tumor. The availability of an ascites variant of this tumor was particularly useful, providing an abundant source of cells for immunization and a target cell population for cytotoxic tests with >95% viability that does not require removal of dead cells by proteolytic enzymes. Another advantage is that Meth A ascites (in contrast to the original solid tumor) does not express MuLV antigens, and cultured lines derived from it remain MuLV⁻. The disadvantage of this system, of course, is that Meth A is a long-transplanted tumor that has had ample time to diverge from the strain of origin during the 17-yr since its induction. However, as the original solid tumor and the ascites variant which have had a separate passage history for the past 16 yr continue to share the same antigen, this would indicate a high degree of coding stability for Meth A antigen. Nevertheless, the conclusions derived from the study of Meth A will have to be confirmed with a series of newly derived sarcomas.

Absorption analysis has not as yet given any clues regarding the origin of the Meth A antigen. There has been speculation that the specific antigens of chemically induced tumors and other tumors as well might represent derepressed fetal antigens, modified antigens of the *H-2* complex, or derepressed

alloantigens (e.g., anomalous appearance of TL antigens in leukemias of TL⁻ strains [34]). Another possibility in view of the extensive polymorphism of MuLV is that MuLV genetic information (e.g., from recombination or mutational events) might be responsible for the unique antigens of chemically induced tumors. The fact that no other normal or malignant tissue, adult or fetal, MuLV⁺ or MuLV⁻, expressed Meth A antigen provides no help in distinguishing these possibilities. Biochemical characterization of Meth A antigen now that serological reagents are available may be more revealing.

Summary

As background for a serological definition of the unique antigens of chemically induced sarcomas, we have typed a series of fibroblast and sarcoma cell lines of BALB/c and C57BL/6 origin by cytotoxicity and absorption tests for murine leukemia virus (MuLV)-related cell surface antigens and known alloantigens. 7 of the 17 cultured lines expressed the range of cell surface antigens associated with MuLV (G_{IX}, GCSA, gp70, p30), and this was invariably associated with MuLV production. In nonproducer lines of C57BL/6 (but not BALB/c) origin, a MuLV-gp70-like molecule was found on the surface of fibroblasts and sarcoma cells. The alloantigenic phenotype of these MuLV⁺ and MuLV⁻ cell lines was H-2D⁺, H-2K⁺, Thy-1.2⁺ or ⁻, PC.1⁺ or ⁻, Lyt-1.2⁻, Lyt-2.2⁻, Ia.7⁻, and TL.2⁻. A unique antigen was defined on the BALB/c ascites sarcoma Meth A with antisera prepared in BALB/c or (BALB/c × C57BL/6)F₁ mice. Tissue culture lines derived from this tumor were MuLV⁻, which facilitated serological study of the antigen. Absorption analysis indicated that the antigen was restricted to Meth A; it could not be detected in normal or fetal BALB/c tissue, MuLV⁺ or MuLV⁻ fibroblast lines, 12 syngeneic or allogeneic sarcomas, or normal lymphoid cells from 13 different inbred mouse strains.

We wish to express our thanks to Dr. Elisabeth Stockert and Dr. Herbert F. Oettgen for advice and support, and to Dr. Paul V. O'Donnell for performing the XC plaque tests.

Received for publication 3 May 1977.

References

1. Gross, L. 1943. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. *Cancer Res.* 3:326.
2. Foley, E. J. 1953. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. *Cancer Res.* 13:835.
3. Prehn, R. T., and J. M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. *J. Natl. Cancer Inst.* 18:769.
4. Klein, G., H. O. Sjögren, E. Klein, and K. E. Hellström. 1960. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. *Cancer Res.* 20:1561.
5. Old, L. J., E. A. Boyse, D. A. Clarke, and E. Carswell. 1962. Antigenic properties of chemically induced tumors. *Ann. N. Y. Acad. Sci.* 101:80.
6. Old, L. J., and E. A. Boyse. 1965. Antigens of tumors and leukemias induced by viruses. *Fed. Proc.* 24:1009.
7. Whitmire, C. E., R. A. Salerno, L. S. Rabstein, R. J. Huebner, and H. C. Turner. 1971. RNA tumor-virus antigen expression in chemically induced tumors. *Virus-*

- genome-specified common antigens detected by complement fixation in mouse tumors induced by 3-methylcholanthrene. *J. Natl. Cancer Inst.* 47:1255.
8. Grant, J. P., D. D. Bigner, P. J. Fischinger, and D. P. Bolognesi. 1974. Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. *Proc. Natl. Acad. Sci. U. S. A.* 71:5037.
 9. Aoki, T., E. A. Boyse, and L. J. Old. 1966. Occurrence of natural antibody to the G (Gross) leukemia antigen in mice. *Cancer Res.* 26:1415.
 10. Ihle, J. N., M. Yurconic, Jr., and M. G. Hanna, Jr. 1973. Autogenous immunity to endogenous RNA tumor virus. Radioimmune precipitation assay of mouse serum antibody levels. *J. Exp. Med.* 138:194.
 11. Nowinski, R. C., and S. L. Kaehler. 1974. Antibody to leukemia virus: widespread occurrence in inbred mice. *Science (Wash. D. C.)*. 185:869.
 12. Shiku, H., M. A. Bean, L. J. Old, and H. F. Oettgen. 1975. Cytotoxic reactions of murine lymphoid cells studied with a tritiated proline microcytotoxicity test. *J. Natl. Cancer Inst.* 54:415.
 13. Old, L. J., E. A. Boyse, and E. Stockert. 1965. The G (Gross) leukemia antigen. *Cancer Res.* 25:813.
 14. Old, L. J., E. A. Boyse, and E. Stockert. 1963. Antigenic properties of experimental leukemias. I. Serological studies *in vitro* with spontaneous and radiation-induced leukemias. *J. Natl. Cancer Inst.* 31:977.
 15. Takahashi, T., L. J. Old, and E. A. Boyse. 1970. Surface alloantigens of plasma cells. *J. Exp. Med.* 131:1325.
 16. Geering, G., L. J. Old, and E. A. Boyse. 1966. Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of Gross virus and other murine leukemia viruses. *J. Exp. Med.* 124:753.
 17. Stockert, E., L. J. Old, and E. A. Boyse. 1971. The G_{IX} system. A cell surface alloantigen associated with murine leukemia virus: implications regarding chromosomal integration of the viral genome. *J. Exp. Med.* 133:1334.
 18. Klein, J. 1975. Biology of the mouse histocompatibility-2 complex. Springer-Verlag New York, Inc., New York.
 19. David, C. S., D. C. Shreffler, and J. A. Frelinger. 1973. New lymphocyte antigen system (LNA) controlled by the *Ir* region of the mouse *H-2* complex. *Proc. Natl. Acad. Sci. U. S. A.* 70:2509.
 20. David, C. S. 1976. Serological and genetic aspects of murine Ia antigens. *Transplant. Rev.* 30:299.
 21. Boyse, E. A., M. Miyazawa, T. Aoki, and L. J. Old. 1968. Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. *Proc. R. Soc. Ser. B.* 170:175.
 22. Shiku, H., P. Kisielow, M. A. Bean, T. Takahashi, E. A. Boyse, H. F. Oettgen, and L. J. Old. 1975. Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity *in vitro*. Evidence for functional heterogeneity related to the surface phenotype of T cells. *J. Exp. Med.* 141:227.
 23. Reif, A. E., and J. M. V. Allen. 1964. The AKR thymic antigen and its distribution in leukemias and nervous tissues. *J. Exp. Med.* 120:413.
 24. Boyse, E. A., E. Stockert, and L. J. Old. 1969. Properties of four antigens specified by the *T1a* locus. Similarities and differences. *Int. Convoc. Immunol.* Buffalo, New York. 353.
 25. Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci.* 72:3666.
 26. O'Donnell, P. V., and E. Stockert. 1976. Induction of G_{IX} antigen and Gross cell surface antigen after infection by ecotropic and xenotropic murine leukemia viruses *in vitro*. *J. Virol.* 20:545.

27. Bloom, E. T. 1970. Quantitative detection of cytotoxic antibodies against tumor-specific antigens of murine sarcomas induced by 3-methylcholanthrene. *J. Natl. Cancer Inst.* 44:443.
28. Rowe, W. P., W. E. Pugh, and J. W. Hartley. 1970. Plaque assay techniques for murine leukemia viruses. *Virology.* 42:1136.
29. Stephenson, J. R., R. K. Reynolds, and S. A. Aaronson. 1972. Isolation of temperature-sensitive mutants of murine leukemia virus. *Virology.* 48:749.
30. Tung, J.-S., E. Fleissner, E. S. Vitella, and E. A. Boyse. 1975. Expression of murine leukemia virus envelope glycoprotein gp69/71 on mouse thymocytes. Evidence for two structural variants distinguished by presence vs. absence of G_{IX} antigen. *J. Exp. Med.* 142:518.
31. Invernizzi, G., and G. Parmiani. 1975. Tumour-associated transplantation antigens of chemically induced sarcomata cross reacting with allogeneic histocompatibility antigens. *Nature (Lond.).* 254:713.
32. Parmiani, G., and G. Invernizzi. 1975. Alien histocompatibility determinants on the cell surface of sarcomas induced by methylcholanthrene. I. *In vivo* studies. *Int. J. Cancer.* 16:756.
33. Martin, W. J., T. G. Gipson, S. E. Martin, and J. M. Rice. 1976. Derepressed alloantigen on transplacentally induced lung tumor coded for by H-2 linked gene. *Science (Wash. D. C.).* 194:532.
34. Old, L. J., and E. A. Boyse. 1973. Current enigmas in cancer research. *Harvey Lect.* 67:273.
35. Boyse, E. A., and L. J. Old. 1976. The immunogenetics of differentiation in the mouse. *Harvey Lect.* In press.
36. Globerson, A., and M. Feldman. 1963. Antigenic specificity of benzo[a]pyrene-induced sarcomas. *J. Natl. Cancer Inst.* 32:1229.